
Tumor-induced osteomalacia (TIO), a rare condition from tumors secreting fibroblast growth factor 23, causes low phosphates, weak bones, and impaired function. A 144-week study with burosumab showed improved skeletal health, mobility, and quality of life in 14 patients. Interviews with 8 participants revealed pain, fatigue, and quality of life as crucial concerns. Pain and fatigue reduction post-treatment was significant, as were improvements in physical well-being.
Like
Save
Share